Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.46 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6854100 | 1.00 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL70114 | 0.82 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| Water SCHEMBL17731583 | 0.81 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6851929 | 0.79 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6847942 | 0.79 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL9191311 | 0.77 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6850593 | 0.75 | RAB9A (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6850600 | 0.75 | RAB9A (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6880030 | 0.74 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6880034 | 0.74 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | NPC1 2962/4885RAB9A 982/4885SMN1; SMN2 4073/4885 |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | Q6ZSR9, KDM4E, HK1 | NPC1 3291/4885RAB9A 485/4885SMN1; SMN2 4344/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | NPC1 3251/4885RAB9A 442/4885SMN1; SMN2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.